Loading stock…

Teva Pharmaceutical Industries Limited (TEVA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Teva Pharmaceutical Industries Limited

TEVAMarket cap $46BPrice $39.1

Country🇮🇱Israel

SectorHealthcare

IndustryPharmaceuticals

Makes generic drugs that copy brand-name medications once patents expire, serving patients worldwide with affordable alternatives. Controls about 10% of the global generic drug market, making essential medicines accessible.

In Bastion Portfolios?

52W Return+103%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+5%5

Revenue Forecast

Rev CAGR (1y)-4%2

Rev CAGR (3y)+2%2

Rev CAGR (5y)+3%2

Earnings Forecast

EPS Growth Y+1+67%10

EPS Growth Y+2+55%9

EPS Growth Y+3+14%7

Quality

Margins

EBIT Margin19%7

Net Income Margin4%3

Free Cash Flow Margin8%5

Debt

Net Debt/EBITDA3.03

Efficiency

ROE10%4

ROA2%4

Earnings Stability44

GEAR+WEAK21

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)146

P/E Ratio (Forward 3y)117

P/BV5.93

EV Multiples

EV/EBITDA Fwd144

EV/EBIT Fwd165

Yield

Free Cash Flow Yield3.0%5

Dividend Yieldna–

Momentum

Short term

1 month return+6%9

3 month return+19%9

YTD return+37%9

Mid term

Price vs 52wHigh96%10

1 year return+96%10

Long term

3 year return+284%10

5 year return+303%10

Risk Shield

Price Risk

Beta-0.610

Volatility157%1

Free Cash Flow

Free Cash Flow Margin8%5

Free Cash Flow Yield3.0%5

Quality

ROCE12%7

Earnings Stability44

Net Debt/EBITDA3.03

02Growth

Is it actually growing, and how fast?

TEVATeva Pharmaceutical Industries

Revenue FY25$17.3B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+67%10

EPS growth, FY27E+55%9

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 55%/yr vs revenue 2%/yr), so margins should widen.

WATCH

Revenue grew 5%/yr over the last 3 years; forecasts see it cooling to 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

TEVATeva Pharmaceutical Industries

Total return Current12.8%

Price return Current7.9%

MOMENTUM RATING↗

VERY STRONG99 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+19%9

YTD return+37%9

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+96%10

3-year return+284%10

5-year return+303%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +284% over three years and +303% over five, ahead of 90% of the market.

It's up 96% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%), over three months (+19%) and so far this year (+37%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Teva. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TEVATeva Pharmaceutical Industries

Revenue FY25$17.3B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+67%10

EPS growth, FY27E+55%9

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 55%/yr vs revenue 2%/yr), so margins should widen.

WATCH

Revenue grew 5%/yr over the last 3 years; forecasts see it cooling to 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

TEVATeva Pharmaceutical Industries

Total return Current12.8%

Price return Current7.9%

MOMENTUM RATING↗

VERY STRONG99 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+19%9

YTD return+37%9

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+96%10

3-year return+284%10

5-year return+303%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +284% over three years and +303% over five, ahead of 90% of the market.

It's up 96% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%), over three months (+19%) and so far this year (+37%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Teva. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community